Location : Home > Products > Inhibitors of Meditech > Cell Cycle
Name:BMN-673
| Chemical structure | Code NO. |
MT0614 |
 |
Name |
BMN-673 |
Synonym |
Talazoparib; BMN673; BMN 673 | |
CAS NO. |
1207456-01-6 | |
Chemical Formula |
C19H14F2N6O | |
MW |
380.35 | |
Purity |
>98% | |
Solubility(R.T.: 25℃) |
DMSO 75 mg/mL; Water <1 mg/mL; Ethanol <1 mg/mL | |
Stability |
- 20℃, 2 years |
Availability and price
BMN-673 is in stock. Bulk available at low price, welcom to inquire quotation.
We offer big discount for bulk quantities. If you have any other questions or needs, please send email to sales@meditechbs.com. We’ll reply you asap.
Description
BMN 673 is a novel PARP1/2 inhibitor with IC50 of 0.58 nM(PARP1); does not inhibit PARG and is highly sensitive to PTEN mutation.
IC50 Value: 0.58 nM
Target: PARP
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development.
IC50 Value: 0.58 nM
Target: PARP
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development.
References
[1]. Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
[2]. Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Attention
Sold for research purposes only; not for human, medical, veterinary, food or household use.
